Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis.
10.1007/s13238-011-1096-0
- Author:
Zheng ZHOU
1
;
Jun-Ming LIAO
;
Peng ZHANG
;
Jun-Bao FAN
;
Jie CHEN
;
Yi LIANG
Author Information
1. State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China.
- Publication Type:Journal Article
- MeSH:
Arrestins;
antagonists & inhibitors;
metabolism;
Dopamine;
metabolism;
Dopamine Antagonists;
therapeutic use;
Dopamine D2 Receptor Antagonists;
Drug Evaluation, Preclinical;
Electrophoresis, Capillary;
Humans;
Parkinson Disease;
drug therapy;
metabolism;
pathology;
Receptors, Dopamine D2;
metabolism;
Signal Transduction;
beta-Arrestin 2;
beta-Arrestins
- From:
Protein & Cell
2011;2(11):899-905
- CountryChina
- Language:English
-
Abstract:
Parkinson's disease is the second most common neurodegenerative disease in the world. Beta-arrestin-2 has been reported to be an important protein involved in D(2) dopamine receptor desensitization, which is essential to Parkinson's disease. Moreover, the potential value of pharmacological inactivation of G protein-coupled receptor kinase or arrestin in the treatment of patients with Parkinson's disease has recently been shown. We studied the interaction between D(2) dopamine receptor and beta-arrestin-2 and the pharmacological regulation of chemical compounds on such interaction using capillary zone electrophoresis. The results from screening more than 40 compounds revealed three compounds that remarkably inhibit the beta-arrestin-2/D(2) dopamine receptor interaction among them. These compounds are promising therapies for Parkinson's disease, and the method used in this study has great potential for application in large-scale drug screening and evaluation.
